Stocksigma LogoStocksigma Logo

Symbiotec Pharmalab Q1FY27 Performance and Business Expansion Update

Symbiotec Pharmalab debuted on the BSE and NSE on 1st Sep'26 following a Rs. 1,757 Cr IPO at Rs. 988 per share

Symbiotec Pharmalab Q1FY27 Performance and Business Expansion Update

Symbiotec Pharmalab Ltd · Investor Presentation · 22 Sept 2026, 1:17 am

Symbiotec Pharmalab Q1FY27 Performance and Business Expansion Update Symbiotec Pharmalab debuted on the BSE and NSE on 1st Sep'26 following a Rs. 1,757 Cr IPO at Rs. 988 per share. For Q1FY27, consolidated revenue rose 7% YoY to Rs. 218.2 Cr, while reported EBITDA fell to Rs. 45.2 Cr (21% margin) and PAT declined to Rs. 14.1 Cr, impacted by Rs. 35 Cr in unabsorbed opex and depreciation from new pre-revenue businesses. Over 60% of its Rs. 1,475 Cr gross capex is slated to generate commercial revenue over the next 6–12 months.

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements